Post-transplant increase in soluble human leukocyte antigen-G associated with non-severe cardiac allograft vasculopathy

Human Immunology

Volumn 74, Issue 3, 2013, Pages 318-324

  Blanco Garcia R M ^a   Lopez alvarez M R ^a,b   Garrido, I P ^a   Salgado Cecilia, G ^a   Campillo, J A ^a,b   Bolarin J M ^a   Gimeno, L ^a   Muro, M ^a,b   Garcia Alonso A M ^a,b   Martinez Sanchez M V ^a   Bernardo Pisa, M V ^a   Soriano Diaz S ^a,b   Pascual Figal, D A ^a   Alvarez Lopez M R ^a,b   Minguela, A ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; HLA G ANTIGEN;

ADULT; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEART TRANSPLANTATION; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; VIRUS REACTIVATION;

ADULT; AGED; ANTIGENS, CD28; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEART TRANSPLANTATION; HLA-G ANTIGENS; HUMANS; HYPERPLASIA; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; SEVERITY OF ILLNESS INDEX; SOLUBILITY; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TUNICA INTIMA; ULTRASONOGRAPHY, INTERVENTIONAL; VIRUS ACTIVATION;

EID: 84873739153     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2012.12.001     Document Type: Article

References (39)

1. Caforio A.L., Tona F., Fortina A.B., Angelini A., Piaserico S., Gambino A., et al. Immune and nonimmune predictors of cardiac allograft vasculopathy onset and severity: multivariate risk factor analysis and role of immunosuppression. Am J Transplant 2004, 4:962-970.
2. Mitchell R.N. Graft vascular disease: immune response meets the vessel wall. Annu Rev Pathol 2009, 4:19-47.
3. Carosella E.D., Moureau P., Le Maoult J., Le Discorde M., Dausset J., Rouas-Freiss N. HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. Adv Immunol 2003, 81:199-252.
4. Lila N., Carpentier A., Amrein C., Khalil-Daher I., Dausset J., Carosella E.D. Implication of HLA-G molecule in heart-graft acceptance. Lancet 2000, 355:2138.
5. Lila N., Amrein C., Guillemain R., Chevalier P., Latremouille C., Fabiani J.N., et al. Human leukocyte antigen-G expression after heart transplantation is associated with a reduced incidence of rejection. Circulation 2002, 105:1949-1954.
6. Lila N., Amrein C., Guillemain R., Chevalier P., Fabiani J.N., Carpentier A. Soluble human leukocyte antigen-G: a new strategy for monitoring acute and chronic rejections after heart transplantation. J Heart Lung Transplant 2007, 26:421-422.
7. Rouas-Freiss N., Naji A., Durrbach A., Carosella E.D. Tolerogenic functions of human leukocyte antigen G: from pregnancy to organ and cell transplantation. Transplantation 2007, 84:S21-5.
8. LeMaoult J., Zafaranloo K., Le Danff C., Carosella E.D. HLA-G upregulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. FASEB J 2005, 19:662-664.
9. Le Gal F.A., Riteau B., Sedlik C., Khalil-Daher I., Menier C., Dausset J., et al. HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes. Int Immunol 1999, 11:1351-1356.
10. Bainbridge D., Ellis S.A., Sargent I.L. HLA-G suppresses proliferation of CD4(+) T-lymphocytes. J Reprod Immunol 2000, 48:17-26.
11. Rouas-Freiss N., Marchal R.E., Kirszenbaum M., Dausset J., Carosella E.D. The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors?. Proc Natl Acad Sci USA 1997, 94:5249-5254.
12. Ristich V., Liang S., Zhang W., Wu J., Horuzsko A. Tolerization of dendritic cells by HLA-G. Eur J Immunol 2005, 35:1133-1142.
13. Le Maoult J., Krawice-Radanne I., Dausset J., Carosella E.D. HLA-G1-expressing antigen-presenting cells induce immunosuppressive CD4+ T cells. Proc Natl Acad Sci USA 2004, 101:7064-7069.
14. Naji A., Le Rond S., Durrbach A., Krawice-Radanne I., Creput C., Daouya M., et al. CD3+CD4 low and CD3+CD8 low are induced by HLA-G: novel human peripheral blood suppressor T-cell subsets involved in transplant acceptance. Blood 2007, 110:3936-3948.
15. Le Rond S., Azema C., Krawice-Radanne I., Durrbach A., Guettier C., Carosella E.D., et al. Evidence to support the role of HLA-G5 in allograft acceptance through induction of immunosuppressive/regulatory T cells. J Immunol 2006, 176:3266-3276.
16. Yan W.H., Lin A., Chen B.G., Chen S.Y. Induction of both membrane-bound and soluble HLA-G expression in active human cytomegalovirus infection. J Infect Dis 2009, 200:820-826.
17. Onno M., Pangault C., Le Friec G., Guilloux V., André P., Fauchet R. Modulation of HLA-G antigens expression by human cytomegalovirus: specific induction in activated macrophages harbouring human cytomegalovirus infection. J Immunol 2000, 164:6426-6434.
18. Gredmark S., Söderberg-Nauclér C. Human cytomegalovirus inhibits differentiation of monocytes into dendritic cells with the consequence of depressed immunological functions. J Virol 2003, 77:10943-10956.
19. Rickenbacher P.R., Pinto F.J., Lewis N.P., Hunt S.A., Alderman E.L., Schroeder J.S., et al. Prognostic importance of intimal thickness as measured by intracoronary ultrasound after cardiac transplantation. Circulation 1995, 92:3445-3452.
20. Lang R.M., Bierig M., Devereux R.B., Flachskampf F.A., Foster E., Pellikka P.A., et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005, 18:1440-1463.
21. Garrido I.P., García-Lara J., Pinar E., Pastor-Pérez F., Sánchez-Mas J., Valdés-Chavarri M., et al. Optical coherence tomography and highly sensitive troponin T for evaluating cardiac allograft vasculopathy. Am J Cardiol 2012, 110:655-661.
22. St.Goar F.G., Pinto F.J., Alderman E.L., Valantine H.A., Schroeder J.S., Gao S.Z., et al. Intracoronary ultrasound in cardiac transplant recipients: in vivo evidence of angiographically silent intimal thickening. Circulation 1992, 85:979-987.
23. Stewart S., Winters G.L., Fishbein M.C., Tazelaar H.D., Kobashigawa J., Abrams J., et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005, 24:1710-1720.
24. Minguela A., Marín L., Torío A., Muro M., García-Alonso A.M., Moya-Quiles M.R., et al. CD28/CTLA-4 and CD80/CD86 costimulatory molecules are mainly involved in acceptance or rejection of human liver transplant. Hum Immunol 2000, 61:658-669.
25. Colovai A.I., Mirza M., Vlad G., Wang S., Ho E., Cortesini R., et al. Regulatory CD8+CD28- T cells in heart transplant recipients. Hum Immunol 2003, 64:31-37.
26. Blanco-García R.M., López-álvarez M.R., Garrido I.P., Salgado-Cecilia G., Campillo J.A., Bolarín J.M., et al. CD28 and KIR2D receptors as sensors of the immune status in heart and liver transplantation. Hum Immunol 2011, 72:841-848.
27. Luque J., Torres M.I., Aumente M.D., Marín J., García-Jurado G., González R., et al. Soluble HLA-G in heart transplantation: their relationship to rejection episodes and immunosuppressive therapy. Hum Immunol 2006, 6:257-263.
28. Gregori S., Magnani C.F., Roncarolo M.G. Role of human leukocyte antigen-G in the induction of adaptive type 1 regulatory T cells. Hum Immunol 2009, 70:966-969.
29. Moreau P., Flajollet S., Carosella E.D. Non-classical transcriptional regulation of HLA-G: an update. J Cell Mol Med 2009, 13:2973-2989.
30. Moreau P., Adrian-Cabestre F., Menier C., Guiard V., Gourand L., Dausset J., et al. IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes. Int Immunol 1999, 11:803-811.
31. Spencer J.V., Lockridge K.M., Barry P.A., Lin G., Tsang M., Penfold M.E., et al. Potent immunosuppressive activities of cytomegalovirus-encoded interleukin-10. J Virol 2002, 76:1285-1292.
32. Valantine H. The role of viruses in cardiac allograft vasculopathy. Am J Transplant 2004, 4:169-177.
33. Weill D. Role of cytomegalovirus in cardiac allograft vasculopathy. Transplant Infect Dis 2001, 3:S44-8.
34. Potena L., Holweg C.T., Chin C., Luikart H., Weisshaar D., Narasimhan B., et al. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. Transplantation 2006, 82:398-405.
35. Luckraz H., Charman S.C., Wreghitt T., Wallwork J., Parameshwar J., Large S.R. Does cytomegalovirus status influence acute and chronic rejection in heart transplantation during the ganciclovir prophylaxis era?. J Heart Lung Transplant 2003, 22:1023-1027.
36. Mahle W.T., Fourshee M.T., Naftel D.M., Alejos J.C., Caldwell R.L., Uzark K., et al. Pediatric heart transplant study group. Does cytomegalovirus serology impact outcome after pediatric heart transplantation?. J Heart Lung Transplant 2009, 28:1299-1305.
37. Wenke K., Meiser B., Thiery J., Nagel D., von Scheidt W., Krobot K., et al. Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation 2003, 107:93-97.
38. Eisen H.J., Tuzcu E.M., Dorent R., Kobashigawa J., Mancini D. Valantine-von Kaeppler HA et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003, 349:847-858.
39. Topilsky Y., Hasin T., Raichlin E., Boilson B.A., Schirger J.A., Pereira N.L., et al. Sirolimus as primary immunosuppression attenuates allograft vasculopathy with improved late survival and decreased cardiac events after cardiac transplantation. Circulation 2012, 125:708-720.